TCON News and Press, TRACON Pharmaceuticals Inc. From 12/27/22

Penny Stocks To Buy According To Analysts As the stock market continues to become more and more unpredictable, it’s increasingly important for traders to use every available tool. Whether you’re trading penny stocks or higher-priced shares, one of those tools is analyst insi...

TRACON Pharmaceuticals ( NASDAQ: TCON ) announced entry into an up to $30M non-recourse financing agreement. $3.5M will be funded before December 31, 2022. The additional $26.5M, or a lesser amount based on the amount awarded, will be available subject to the award exceeding a thr...

SAN DIEGO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life scie...

Tracon Pharma ( NASDAQ: TCON ) is trading ~17% higher premarket after the company announced positive data from a phase 2 trial testing its drug, Envafolimab, as monotherapy and in combination with Yervoy, to treat solid tumors. The Independent Data Monitoring Co...

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold Enrollment Continues Ahead of Schedule; Next Interim Analysis Expected in mid-2023 with Full Accrual Now Expected Before the End of 2023 Arbi...

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...

Tracon press release ( NASDAQ: TCON ): Q3 GAAP EPS of -$0.30 beats by $0.02 . Cash and cash equivalents were $17.0M at September 30, 2022, compared to $24.1M at December 31, 2021, and is expected to fund the company into mid-2023. For further details see: Tra...

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Conference Call November 14, 2022, 16:30 ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. ...

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...